alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–21 of 21 studies with an author at University of Leeds (GB) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Interventions for preventing delirium in hospitalised patients

✓ Peer-reviewed alzhub usefulness score 69 out of 100. The Cochrane database of systematic reviews 2007-04-18

It is associated with increases in mortality, physical morbidity, length of hospital stay, institutionalisation and costs to healthcare providers. 4 key findings →

Participants: 833 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Nature Genetics 2011-04-03

The authors sought to identify new susceptibility loci for Alzheimer's disease through a staged association study and by testing suggestive loci reported by the Alzheimer's Disease Genetic Consortium in a companion paper. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Neurology 2000-04-01

The authors recruited 83 patients with PD and 50 controls, all without dementia at initial assessment, and assessed them at regular intervals over a maximum period of 122 months. 4 key findings →

Participants: 83 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Comorbidity Trajectories Before and After the Diagnosis of Heart Failure: A UK Biobank Cohort Study

✓ Peer-reviewed alzhub usefulness score 51 out of 100. European Journal of Heart Failure 2025-02-11

We identified all participants in the UK Biobank cohort study diagnosed with HF prior to enrolment or during follow-up, who had disease occurrence data available from both primary and secondary care records (n = 9824). 5 key findings →

Design: cohort study Participants: 9,824 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cognitive impairment in Parkinson disease: impact on quality of life, disability, and caregiver burden

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Journal of geriatric psychiatry and neurology 2012-11-21

Both quality of life and caregiver burden were similar in the 2 groups without dementia but were significantly different in those with PDD. 3 key findings →

Participants: 54 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Associations between falls and other serious adverse events and antihypertensive medication in individuals with dementia: An observational cohort study

✓ Peer-reviewed alzhub usefulness score 49 out of 100. PLoS Medicine 2025-09-17

This was a retrospective analysis using nationally representative UK general practice population between 1998 and 2018, from electronic health records (Clinical Practice Research Datalink, CPRD, GOLD). 5 key findings →

Participants: 1,219,732 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Parkinson's disease iron deposition caused by nitric oxide-induced loss of β-amyloid precursor protein

✓ Peer-reviewed alzhub usefulness score 48 out of 100. The Journal of neuroscience : the official journal of the Society for Neuroscience 2015-02-01

Elevation of both neuronal iron and nitric oxide (NO) in the substantia nigra are associated with Parkinson's disease (PD) pathogenesis. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

TGF-β Pathway–Based Polygenic Risk Score Modifies the Association between Red Meat Intake and Colorectal Cancer Risk: Application of a Novel Pathway-Based PRS Method

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Cancer Epidemiology Biomarkers & Prevention 2026-04-01

A total of 30 variants were overrepresented in four pathways: presenilin/Alzheimer disease, cadherin/WNT signaling, gonadotropin-releasing hormone receptor, and transforming growth factor-β (TGF-β) signaling. 5 key findings →

Participants: 204 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The relationship between obesity and cognitive health and decline

✓ Peer-reviewed alzhub usefulness score 46 out of 100. The Proceedings of the Nutrition Society 2017-09-11

The relationship between obesity and cognitive impairment is important given the globally ageing population in whom cognitive decline and neurodegenerative disorders will carry grave individual, societal and financial burdens. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Prion protein-mediated toxicity of amyloid-β oligomers requires lipid rafts and the transmembrane LRP1

✓ Peer-reviewed alzhub usefulness score 46 out of 100. The Journal of biological chemistry 2013-02-05

Soluble oligomers of the amyloid-β (Aβ) peptide cause neurotoxicity, synaptic dysfunction, and memory impairments that underlie Alzheimer disease (AD). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The amyloid precursor protein: a biochemical enigma in brain development, function and disease

✓ Peer-reviewed alzhub usefulness score 45 out of 100. FEBS letters 2013-05-16

For 20 years the amyloid cascade hypothesis of Alzheimer disease (AD) has placed the amyloid-β peptide (Aβ), formed from the amyloid precursor protein (APP), centre stage in the process of neurodegeneration. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 43 out of 100. EMBO reports 2008-12-05

Amyloid beta-peptide (Abeta) accumulation leads to neurodegeneration and Alzheimer disease; however, amyloid metabolism is a dynamic process and enzymic mechanisms exist for Abeta removal. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

“There is always a reason why someone is doing something”: The importance of life history and personhood when supporting people with dementia to “wander” in care homes

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Dementia 2025-01-27

Up to 60% of people living with dementia who reside in care homes will ‘wander’ at some point. 1 key finding →

Participants: 19 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Stalling life expectancy and increased mortality in working ages deserve urgent attention

✓ Peer-reviewed alzhub usefulness score 36 out of 100. The Lancet Public Health 2019-11-01

The effect of austerity and associated budgets are strong contenders,3Ruckert A Labonté R Health inequities in the age of austerity: the need for social protection policies. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Genetic analysis of Down syndrome facilitated by mouse chromosome engineering

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Bioengineered bugs 2012-01-01

Human trisomy 21 is the most frequent live-born human aneuploidy and causes a constellation of disease phenotypes classified as Down syndrome, which include heart defects, myeloproliferative disorder, cognitive disabilities and Alzheimer-type neurodegeneration. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed